|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0010181,
umls-concept:C0018696,
umls-concept:C0039286,
umls-concept:C0043210,
umls-concept:C0087111,
umls-concept:C0205195,
umls-concept:C0205197,
umls-concept:C0205225,
umls-concept:C0232970,
umls-concept:C0290883,
umls-concept:C0677850,
umls-concept:C0878174,
umls-concept:C0936012,
umls-concept:C1363878,
umls-concept:C1556116,
umls-concept:C1556117,
umls-concept:C1710684,
umls-concept:C2348557
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-10-31
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
This study evaluated the cost-effectiveness of anastrozole versus generic tamoxifen for primary adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) early breast cancer (EBC), from a US healthcare perspective.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0167-6806
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
229-38
|
|
pubmed:dateRevised |
2008-4-14
|
|
pubmed:meshHeading |
pubmed-meshheading:17245540-Antineoplastic Agents, Hormonal,
pubmed-meshheading:17245540-Breast Neoplasms,
pubmed-meshheading:17245540-Chemotherapy, Adjuvant,
pubmed-meshheading:17245540-Cost-Benefit Analysis,
pubmed-meshheading:17245540-Drug Costs,
pubmed-meshheading:17245540-Female,
pubmed-meshheading:17245540-Great Britain,
pubmed-meshheading:17245540-Health Services Research,
pubmed-meshheading:17245540-Humans,
pubmed-meshheading:17245540-Markov Chains,
pubmed-meshheading:17245540-Middle Aged,
pubmed-meshheading:17245540-Nitriles,
pubmed-meshheading:17245540-Postmenopause,
pubmed-meshheading:17245540-Quality-Adjusted Life Years,
pubmed-meshheading:17245540-Tamoxifen,
pubmed-meshheading:17245540-Triazoles,
pubmed-meshheading:17245540-United States
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
|
|
pubmed:affiliation |
Evanston Northwestern Healthcare, 2650 Ridge Room 5134, Evanston, IL 60201, USA. gylocker@northwestern.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
